Dear Shareholder, We are very pleased to be providing this Investor Update, which details the activities of recent months and plans for the clinical development of Photosoft™ a next generation Photo Dynamic Therapy (PDT) for the treatment of a number of cancers. During 2017, the focus of Invion was to identify and pursue opportunities to…
Read more
Leading ovarian cancer expert Dr Andrew Stephens appointed to Invion’s advisory board
Dr Andrew Stephens from Hudson Institute of Medical Research has accepted an appointment on Invion’s advisory board Dr Stephens is one of Australia’s leading researchers in the area of ovarian cancer and heads the Ovarian Cancer Biomarkers Research Laboratory at Hudson Institute His appointment provides Invion with a substantial resource in developing its licenced cancer…
Read more
Invion secures research alliance with Hudson Institute of Medical Research
Hudson Institute is a leading Australian biomedical research institute recognised internationally for delivering better health through research into cancer and inflammation The alliance is aimed at advancing Invion’s licenced cancer treatment technology, PhotosoftTM Hudson Institute will provide research and clinical expertise on a series of projects in collaboration with Invion Projects will target a range…
Read more
Change of registered office and principal place of business
INVION LIMITED: CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS Invion Limited (ASX:IVX) wishes to advise that, effective 16 March 2018, the registered office and principal place of business for the Company is: Invion Limited 722 High Street East Kew, VIC 3102 Australia The contact and mailing details of the Company change to: Invion…
Read more